The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...
Read more...Looking Good: Immunoassays for Blood Markers
For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...
Read more...
Recent key publications
- 10 April, 2025
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
- 31 March, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
- 28 March, 2025
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
- 4 March, 2025
Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data
X posts
New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @lancetneurology:
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome...
Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to de...
www.thelancet.com
7⃣These findings support implementation of especially plasma p-tau217, and potentially also GFAP, in prognostic workup of AD in people with DS in both clinical practice and drug trials.
A huge thanks to the @abc_ds_ team, all co-authors, and the participants of the study.
🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo from @_JakeVogel_'s group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇
How does the brain reorganize in the context of age and AD?
Are functional changes in age and AD similar?
Are these changes dynamic across the age/AD spectrum?
We unpack these questions in a sample of N=973 with AD biomarkers
Preprint: http://tinyurl.com/ymv8s7h8
1/
⬇️🧵
So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠
🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey: https://alz.surveymonkey.com/r/923BTQK